switch from tirzepatide to semaglutide Switching Switching Tirzepatide to Semaglutide: Clinical

Cookie management Bessesary cookies for the proper functioning of the website

Key safety observations from available trial data include: Elevated resting heart rate in a dose-dependent manner Gastrointestinal adverse effects (nausea, vomiting, diarrhoea) as the most common side effects, consistent with the GLP-1 receptor agonist class [1] [3] No clinically significant QT interval prolongation was reported in available data, though the extent of formal thorough QT assessment has not been fully detailed in published sources

In particular, drug shortages have affected the availability of semaglutide

However, its unique action on glucagon receptors requires further research to assess long-term metabolic effects